Blood test may help overcome barriers to colon cancer screening
NCT ID NCT06444542
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This completed study with 297 participants examined if offering a blood-based screening test (Guardant Shield) encourages people who previously avoided stool tests or colonoscopy to get screened for colorectal cancer. Participants were adults aged 45-75 at average risk who had not completed a recommended screening. The study measured their preference for the blood test and tracked how many chose it over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Penn State College of Medicine
Hershey, Pennsylvania, 17033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guardant Shield blood-based colorectal cancer screening test
What this could lead to
If successful, this could show that a simple blood test boosts screening rates in people who avoid traditional methods, potentially catching more cancers early.
What could go wrong
This is a completed behavioral study, not a treatment trial. It measures preferences and adoption rates, not health outcomes, so it won't directly prove the test saves lives.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.